33 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
6
Great Therapeutic Potential of Peptidylarginine Deiminase 4 (PAD4) Inhibitors: Treatment of Rheumatoid Arthritis, Epigenetic Tools, Regulation of Pluripotency in Stem Cells, and More.
Therachem Research Medilab (India)
1
Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors.
University of Massachusetts Medical School
6
Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation.
The Scripps Research Institute-Florida
1
Interrogation of the Active Sites of Protein Arginine Deiminases (PAD1, -2, and -4) Using Designer Probes.
University Health Network
14
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
University of South Carolina
18
The development of N-a-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-a-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.
The Scripps Research Institute
9
Highly-tumor-targeted PAD4 inhibitors with PBA modification inhibit tumors in vivo by specifically inhibiting the PAD4-H3cit-NETs pathway in neutrophils.
College of Pharmaceutical Sciences of Capital Medical University
42
A β-Carboline Derivate PAD4 Inhibitor Reshapes Neutrophil Phenotype and Improves the Tumor Immune Microenvironment against Triple-Negative Breast Cancer.
Capital Medical University
15
Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein-Ligand Interactions and High Selectivity.
AstraZeneca
17
Privileged heterocycles for DNA-encoded library design and hit-to-lead optimization.
Chinese Academy of Sciences
6
Novel Macrocyclic Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors.
Smith, Gambrell & Russell
10
Peptidylarginine deiminases 4 as a promising target in drug discovery.
Zhejiang Ocean University
7
DNA-Encoded Library Screening as Core Platform Technology in Drug Discovery: Its Synthetic Method Development and Applications in DEL Synthesis.
Daegu-Gyeongbuk Medical Innovation Foundation (Dgmif)
8
Cellular Activity of New Small Molecule Protein Arginine Deiminase 3 (PAD3) Inhibitors.
Yale University
5
Synthesis and Biological Evaluation of an Indazole-Based Selective Protein Arginine Deiminase 4 (PAD4) Inhibitor.
Yale University
7
Inhibitors of protein arginine deiminases and their efficacy in animal models of multiple sclerosis.
University Health Network
10
Noncovalent Protein Arginine Deiminase (PAD) Inhibitors Are Efficacious in Animal Models of Multiple Sclerosis.
University of Toronto
34
Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
Zhuhai United Laboratories Co.
36
N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF
Hangzhou Apeloa Medicine Research Institute Co.
49
FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28
Dana-Farber Cancer Institute
10
CORONAVIRUS MAIN PROTEASE INHIBITORS AND METHODS USING SAME
Baylor College of Medicine
46
Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
Ariad Pharmaceuticals
33
SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model
Sichuan University
18
Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.
Merck Research Laboratories